MONROVIA, Calif. , Dec. 3, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced initial data from its ongoing Phase 1

MONROVIA, Calif. , Nov. 20, 2018 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,

MONROVIA, Calif. , Nov. 8, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced the appointment of Ellen G.

- Initial Data from Phase 1 Dose-Escalation Study of XmAb®14045 in Acute Myeloid Leukemia (AML) to Be Presented at 2018 ASH Annual Meeting - - Plan to Initiate Phase 3 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) by Early 2019 - - Expect to Initiate Phase 1 Studies for Bispecific Tumor

MONROVIA, Calif. , Nov. 1, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced that initial data from its ongoing Phase 1

MONROVIA, Calif. , Oct. 29, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it will release third

- Positive trend in primary endpoint; proportion of efficacy-evaluable patients who did not experience loss of improvement (LOI) by Day 225 did not meet statistical significance (XmAb®5871 42% vs. placebo 28.6%, p = 0.18) - Met secondary endpoint of time to LOI; risk of LOI reduced by 47% for

MONROVIA, Calif. , Sept. 25, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will

- Dosed the First Patient in DUET-2, Phase 1 Clinical Trial of Lead Tumor Microenvironment (TME) Activator XmAb®20717 in Advanced Solid Tumors - - Expect to Announce Topline Data from Phase 2 Trial of XmAb®5871 in Systemic Lupus Erythematosus (SLE) and Initial Data from Phase 1 Trial of XmAb®14045

MONROVIA, Calif. , Aug. 1, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will